Deep learning methods to accelerate discoveryof drugs targeting gene regulatory proteins
Award amount
$398,441Program and phase
SBIR · Phase IAward year
2023Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- TALUS BIOSCIENCE INC
- Proposal award date
- 2023-09-20
- Contract end date
- 2024-08-31
- UEI
- NKSRDDRQK175
- Solicitation number
- PA21-259
- Topic code
- 400
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Activity-based regulome profiling for the discovery of covalent transcription factor inhibitors
- Activity-based regulome profiling for the discovery of covalent transcription factor inhibitors
- Simultaneous pharmacological profiling of oncogenic gene fusion proteins in cancer
- Simultaneous pharmacological profiling of oncogenic gene fusion proteins in cancer
- Illuminating the "dark" kinases - effects on proteome translocation and chromatin binding
Research funding history
7 SBIR/STTR records share this UEI (2021–2024). Reported award amounts total $5,394,162. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, National Science Foundation